Valentino Conter

Azienda Ospedaliera San Gerardo — Italy

Medicine · Health Sciences

54h-index10.8kcitations326works0.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Lymphoblastic Leukemia research(262), Childhood Cancer Survivors' Quality of Life(117), Acute Myeloid Leukemia Research(64), Chronic Myeloid Leukemia Treatments(62), Lymphoma Diagnosis and Treatment(30)

Publications325 total

Reducing Daunorubicin in Induction Therapy in Children With B-Lineage ALL With Favorable Prognosis: Results of Phase III Trial AIEOP-BFM ALL 2009
Journal of Clinical Oncology·2025
Unfavorable outcomes in pediatric PAX5r B-cell precursor acute lymphoblastic leukemia: FLT3 targeting as a potential novel treatment strategy
Blood·2025
A Decade of Transformation in the Management of Childhood Acute Lymphoblastic Leukemia: From Conventional Chemotherapy to Precision Medicine
Pediatric Reports·2025Open Access
Results in pediatric T‐ALL patients treated in trial AIEOP‐BFM ALL 2009: Prognostic factors in the context of modern risk‐adapted therapy
HemaSphere·2025· 1 citedOpen Access
Prospective Evaluation of the Pathologic Diagnosis and Treatment Outcomes of Pediatric Burkitt Lymphoma in the Central American Pediatric Hematology-Oncology Association Consortium
JCO Global Oncology·2025Open Access
Correction to: Acute Lymphoblastic Leukemia in Children and Adolescents
Pediatric oncology·2025Open Access
Eight-year national multicenter experience on the use of glucarpidase as effective rescue therapy for delayed methotrexate elimination after high-dose methotrexate cycles administered in children with hemato-oncological diseases
EJC Paediatric Oncology·2024Open Access
A Reduced Daunorubicin Dose during Induction Is Equally Effective As Standard Dose in Children with Acute Lymphoblastic Leukemia (ALL) and Favorable Prognostic Features: Long-Term Results of the Phase 3 Trial AIEOP-BFM ALL 2009
Blood·2024· 2 cited
Frequency and Early Prognostic Significance of Gene-Class Fusions Identified By RNA-Seq in Children and Adolescent with T-Cell Acute Lymphoblastic Leukemia Enrolled on AIEOP-BFM ALL 2017 Study
Blood·2024Open Access
Results in Pediatric T-ALL Patients Treated in Trial AIEOP-BFM ALL 2009: Exploring Prognostic Factors in the Context of Modern Risk Adapted Therapy
Blood·2024
Supplementary Table S21 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
2024Open Access
Supplementary Methods from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
2024Open Access
Supplementary Table S6 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
2024Open Access
Supplementary Table S14 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
2024Open Access
Supplementary Figure S3 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
2024Open Access
Supplementary Table S15 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
2024Open Access
Supplementary Figure S2 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
2024Open Access
Supplementary Table S18 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
2024Open Access
Supplementary Figure S1 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
2024Open Access
Supplementary Figure S9 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
2024Open Access
page 1 of 17Next →

Frequent Co-authors

Andrea Biondi(26), Maria Grazia Valsecchi(24), Maurizio Aricò(21), Giuseppe Basso(20), Martin Schrappe(18), Giuseppe Masera(18), Carmelo Rizzari(16), Daniela Silvestri(14), Franco Locatelli(11), Giovanni Cazzaniga(11), Andrea Pession(9), Rosanna Parasole(8), Chiara Messina(8), Luca Lo Nigro(8), Anna Maria Testi(8), Martin Zimmermann(7), Elena Barisone(7), Jan Starý(7), Claus R. Bartram(5), Martin Stanulla(5)